• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Phase 3 trial of VR475 inhalation suspension fails to meet primary endpoint, Vectura discontinues development

Vectura has announced that a Phase 3 study of VR475 budesonide inhalation suspension for the treatment of severe uncontrolled asthma in adult and adolescent patients failed to meet its primary endpoint. As a result, the company said that it would discontinue development of VR475 (formerly known as Favolir), which it acquired when it acquired Activaero in … [Read more...] about Phase 3 trial of VR475 inhalation suspension fails to meet primary endpoint, Vectura discontinues development

InCarda Therapeutics raises $42 million, initiates Phase 2 trial of inhaled flecainide

InCarda Therapeutics has announced the completion of an oversubscribed $42 million Series B financing that will fund a Phase 2 study of InRhythm inhaled flecainide for the treatment of recent-onset paroxysmal atrial fibrillation (PAF). The financing round was led by Sofinnova and HealthCap, both new investors along with Deerfield Management. In 2015, InCarda raised … [Read more...] about InCarda Therapeutics raises $42 million, initiates Phase 2 trial of inhaled flecainide

Vectura to develop generic versions of Ellipta DPIs with Hikma

Vectura and Hikma Pharmaceuticals have announced a deal for development and commercialization of generic versions of GSK's Ellipta dry powder inhalers. Hikma will pay Vectura $15 million up front, $5 million at the start of clinical manufacturing for the first product, up to $75 million in development milestones, a percentage of distributable share of net profit on … [Read more...] about Vectura to develop generic versions of Ellipta DPIs with Hikma

Covis Pharma acquires additional rights to Alvesco, Omnaris, and Zetonna from AstraZeneca

AstraZeneca has announced that Covis Pharma will pay $350 million up front for the rights to market Alvesco ciclesonide MDI and the ciclesonide nasal spray Omnaris and nasal MDI Zetonna outside of the US. The deal also includes up to $21 million in potential payments conditioned on sales over the 4 years beginning in 2019. Covis acquired US rights to Alvesco, Omnaris, … [Read more...] about Covis Pharma acquires additional rights to Alvesco, Omnaris, and Zetonna from AstraZeneca

Receptor Life Sciences raises $29 million

Receptor Life Sciences has raised $29 million for development of several cannabinoid products, the company said. In 2016, MannKind Corporation announced that it had licensed its dry powder inhalation technology to Receptor, which was then newly formed. According to the company, "Receptor’s inhalation technology combines a simple-to-use, breath-powered inhaler … [Read more...] about Receptor Life Sciences raises $29 million

Glenmark opens new manufacturing facility in US

Glenmark Pharmaceuticals has officially opened its first US manufacturing site in Monroe, North Carolina, the company said. The 100,000 sq ft, $100 million facility will eventually produce hundreds of millions of doses in various forms annually, including 25-30 million inhalation ampoules. The site currently employs 168 people, and the Glenmark said that it expects … [Read more...] about Glenmark opens new manufacturing facility in US

GSK opens new Ellipta API manufacturing facility in Scotland

According to the Scottish government, a new manufacturing facility built by GSK in Montrose to produce APIs for its Ellipta dry powder inhalers officially opened on October 22, 2018, with Scottish First Minister Nicola Sturgeon in attendance. Sturgeon commented, “This new facility is testament to GSK’s commitment to Montrose and reinforces the region’s position … [Read more...] about GSK opens new Ellipta API manufacturing facility in Scotland

Adapt and Opiant file suit in response to Perrigo ANDA for naloxone nasal spray

Perrigo said that Adapt Pharma and Opiant Pharmaceuticals have initiated patent litigation in the United States District Court for the District of New Jersey in regards to Perrigo's recently filed ANDA for a generic version of Narcan naloxone nasal spray for the treatment of opioid overdose. Adapt Pharma licensed naloxone nasal spray from Opiant (then called … [Read more...] about Adapt and Opiant file suit in response to Perrigo ANDA for naloxone nasal spray

Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor

Galecto Biotech announced that it raised €79 million in a series C financing round that will be used to fund a Phase 2/3 study of its TD139, an inhaled galectin-3 inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). New investors included Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Maverick Ventures, Seventure Partners, and … [Read more...] about Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor

VistaGen acquires second Pherin nasal spray

VistaGen Therapeutics said that it has exercised an option to acquire an exclusive worldwide license for Pherin Pharmaceutical's PH10 intranasal steroid, which is in Phase 2 development for the treatment of major depressive disorder (MDD). According to the company, a Phase 2a study of PH10 conducted by MIchael Liebowitz of Columbia University demonstrated significant … [Read more...] about VistaGen acquires second Pherin nasal spray

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 64
  • Page 65
  • Page 66
  • Page 67
  • Page 68
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews